Laboratorios Leon Farma S.A.
13
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
0%
0 trials in Phase 3/4
0%
2 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.
Role: lead
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Subjects
Role: lead
Bioequivalence of Progesterone Vaginal Insert 100 mg in Healthy Pre-Menopausal, Nonpregnant Female Subjects.
Role: lead
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects.
Role: lead
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects.
Role: lead
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Role: lead
Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fed Conditions
Role: lead
Comparative Bioavailability of Levonorgestrel 52 mg Intrauterine System versus Mirena® in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Role: lead
Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects.
Role: lead
Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fasting Conditions
Role: lead
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants.
Role: lead
Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.
Role: lead
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Role: lead
All 13 trials loaded